新生儿先天性膈疝体外生命支持与生存获益的关联
该回顾性队列研究基于2007至2019年先天性膈疝研究组登记中符合ECLS条件的新生儿,按影响主要结局的风险变量进行倾向评分匹配,比较接受与未接受ECLS者的院内死亡。结果显示,低中危患儿使用ECLS与死亡增加相关,而高危患儿(首日最低可达PaCO2≥60 mm Hg)使用ECLS与生存获益相关,且该获益主要见于高频开展ECLS的高容量中心。
要点
- 低中危CDH新生儿使用ECLS与院内死亡增加相关
- 高危(首日PaCO2≥60 mm Hg)患儿使用ECLS与生存获益相关
- ECLS生存获益主要见于CDH高容量且ECLS经验丰富的中心
核心结论
- 在低危和中危CDH新生儿中,ECLS使用与超额死亡相关。
- 在高危CDH婴儿中,ECLS使用与显著的生存获益相关。
研究设计与样本
- 回顾性队列研究,使用ECLS-eligible CDH Study Group登记中2007至2019年出生的患儿。
- 共纳入5855例符合ECLS条件的CDH患者,其中1701例(29.1%)接受了ECLS。
- 采用迭代倾向评分匹配、生存分析(Cox回归和Kaplan-Meier)及中心效应分析。
主要发现
- 倾向评分匹配后,ECLS组死亡率高于非ECLS组(47.8% vs 21.8%,OR 3.3,95%CI 2.7-4.0,HR 2.3,P<0.0001)。
- 高危亚组中,ECLS组死亡率低于非ECLS组(64.2% vs 84.4%,OR 0.33,95%CI 0.17-0.65,HR 0.33,P=0.001)。
- 高危亚组的ECLS生存优势在多种匹配方法下均持续存在。
关键数值与推荐
- 高危患者定义为首日最低可达动脉血二氧化碳分压≥60 mm Hg。
- 低中危患儿使用ECLS与死亡增加相关(OR 3.3,95%CI 2.7-4.0)。
- 高危患儿使用ECLS与生存获益相关(OR 0.33,95%CI 0.17-0.65,P=0.001)。
临床怎么用
- 对低中危CDH新生儿应谨慎评估ECLS指征,避免不必要使用。
- 对首日PaCO2≥60 mm Hg的高危CDH患儿可考虑ECLS,但需结合中心容量与ECLS经验。
- ECLS决策应纳入中心CDH年收治量与ECLS开展频率等中心因素。
局限性
- 本研究为回顾性队列研究,存在选择偏倚与混杂可能。
- 高危定义基于首日最低可达PaCO2,需在临床中进一步验证。
- ECLS生存获益受中心容量与ECLS经验影响,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To measure the survival among comparable neonates with CDH supported with and without ECLS. SUMMARY OF BACKGROUND DATA: Despite widespread use in the management of newborns with CDH, ECLS has not been consistently associated with improved survival. METHODS: A retrospective cohort study was performed using ECLS-eligible CDH Study Group registry patients born between 2007 and 2019. The primary outcome was in-hospital mortality. Neonates who did and did not receive ECLS were matched based on variables affecting risk for the primary outcome. Iterative propensity score-matched, survival (Cox regression and Kaplan-Meier), and center effects analyses were performed to examine the association of ECLS use and mortality. RESULTS: Of 5855 ECLS-eligible CDH patients, 1701 (29.1%) received ECLS. "High-risk" patients were best defined as those with a lowest achievable first-day arterial partial pressure of CO2 of ≥60 mm Hg. After propensity score matching, mortality was higher with ECLS (47.8% vs 21.8%, odds ratio 3.3, 95% confidence interval 2.7-4.0, hazard ratio 2.3, P < 0.0001). For the subgroup of high-risk patients, there was lower mortality observed with ECLS (64.2% vs 84.4%, odds ratio 0.33, 95% confidence interval 0.17-0.65, hazard ratio 0.33, P = 0.001). This survival advantage was persistent using multiple matching approaches. However, this ECLS survival advantage was found to occur primarily at high CDH volume centers that offer frequent ECLS for the high-risk subgroup. CONCLUSIONS: Use of ECLS is associated with excess mortality for low- and intermediate-risk neonates with CDH. It is associated with a significant survival advantage among high-risk infants, and this advantage is strongly influenced by center CDH volume and ECLS experience.
引用
- Jancelewicz T, Langham MR, Brindle ME, et al. Survival Benefit Associated With the Use of Extracorporeal Life Support for Neonates With Congenital Diaphragmatic Hernia. Ann Surg. 2022. PMID: 33060376. doi:10.1097/SLA.0000000000003928
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。